EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mechanisms of Resistance to PARPi in Pancreatic Ductal Adenocarcinoma

Jojanneke Stoof iD, Charlotte Andrieu iD, Fiona O'Connell, Jacintha O'Sullivan, Maeve A Lowery, Naomi Walsh

Journal of Cellular and Molecular Medicine · 2025-08 · 29 (16)

DOI: 10.1111/jcmm.70816 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 28.08.2025. Verfasst von Jojanneke Stoof und 5 weiteren Autor:innen. Beteiligte Einrichtung: Trinity St. James Cancer Institute, Trinity College Dublin, Dublin, Ireland. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Carcinoma, Pancreatic Ductal, Poly(ADP-ribose) Polymerase Inhibitors, Pancreatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020 Framework Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal disease with limited treatment options. PARP inhibitors (PARPi) have shown promise in treating PDAC with homologous recombination deficiency (HRD), but rapid acquisition of resistance limits their efficacy. Our objective is to investigate mechanisms of resistance to PARPi in BRCA2 ‐mutant PDAC cells and identify potential therapeutic targets to modulate this resistance. We developed olaparib‐ and talazoparib‐resistant Capan‐1 cell lines and characterised their resistance profiles using viability assays, RNA sequencing and metabolomic profiling. We also developed a cisplatin‐resistant Capan‐1 cell line to compare resistance mechanisms between PARPi and platinum agents. Both olaparib‐ and talazoparib‐resistant cells showed cross‐resistance to other PARPi and oxaliplatin, but not to gemcitabine or 5‐FU. Talazoparib‐resistant cells exhibited a similar resistance profile to cisplatin‐resistant cells, including decreased PARP1 expression and altered metabolomic profiles. RNA sequencing and metabolomic profiling revealed significant enrichment of metabolic pathways, including oxidative phosphorylation and glycolysis, in resistant cells. Our study highlights the complexity of resistance mechanisms to PARPi in PDAC and identifies potential therapeutic targets in metabolism. The differences in the resistance profiles between olaparib and talazoparib suggest that PARP‐trapping potency may play a role in resistance development. Further research is needed to validate these findings and explore novel therapeutic strategies to overcome resistance to PARPi in PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmCarcinoma, Pancreatic DuctalPoly(ADP-ribose) Polymerase InhibitorsPancreatic NeoplasmsHumansCell Line, TumorPhthalazinesPiperazinesCisplatinGene Expression Regulation, NeoplasticPoly (ADP-Ribose) Polymerase-1OxaliplatinBRCA2 ProteinDeoxycytidineMetabolomicsAntineoplastic AgentsGemcitabine

Stichwörter der Autor:innen

PARP inhibitorcisplatinmetabolismpancreatic ductal adenocarcinomaresistance

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsPhthalazinesolaparibPiperazinesCisplatintalazoparibPoly (ADP-Ribose) Polymerase-1OxaliplatinBRCA2 ProteinDeoxycytidine

Autor:innen und Institutionen

  • Trinity St. James Cancer Institute, Trinity College Dublin, Dublin, Ireland.
  • School of Biotechnology, Life Sciences Institute, Dublin City University, Dublin, Ireland.

ORCID-Profile: Jojanneke Stoof, Charlotte Andrieu

Förderung

  • Horizon 2020 Framework Programme

Zitieren

APA

Stoof, J., Andrieu, C., O'Connell, F., O'Sullivan, J., Lowery, M. A., & Walsh, N. (2025). Mechanisms of Resistance to PARPi in Pancreatic Ductal Adenocarcinoma. Journal of Cellular and Molecular Medicine, 29(16). https://doi.org/10.1111/jcmm.70816

Vancouver

Stoof J, Andrieu C, O'Connell F, O'Sullivan J, Lowery MA, Walsh N. Mechanisms of Resistance to PARPi in Pancreatic Ductal Adenocarcinoma. Journal of Cellular and Molecular Medicine. 2025;29(16). doi:10.1111/jcmm.70816

BibTeX
@article{Stoof2025,
  author = {Stoof, Jojanneke and Andrieu, Charlotte and O'Connell, Fiona and O'Sullivan, Jacintha and Lowery, Maeve A and Walsh, Naomi},
  title = {Mechanisms of Resistance to PARPi in Pancreatic Ductal Adenocarcinoma},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2025},
  volume = {29},
  number = {16},
  doi = {10.1111/jcmm.70816}
}
Kostenlos starten →